Ticker Hub
BMRN — AI Analysis & Sentiment
5 recent AI-generated analyses for BMRN. Sentiment and confidence insights updated continuously.
BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO® (vosoritide) in Children with Hypochondroplasia
BioMarin announced highly positive Phase 3 results for VOXZOGO in hypochondroplasia, an underserved market. This significantly expands the drug's p...
May 20, 2026BioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 Deficiency
BioMarin's Phase 3 trial for BMN 401 failed a crucial clinical endpoint, a major setback for its rare disease pipeline. The market's muted initial ...
May 18, 2026BioMarin Completes Acquisition of Amicus Therapeutics
BioMarin's acquisition of Amicus Therapeutics significantly expands its rare disease portfolio with established and pipeline products. This complet...
Apr 27, 2026BioMarin Presents New Data on the Positive Impact of Early Treatment With VOXZOGO® (vosoritide) on Proportionality and Arm Span in Children with Achondroplasia at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting
BioMarin's new data reinforces VOXZOGO's efficacy, especially with early treatment for achondroplasia. This strengthens the drug's long-term commer...
Mar 12, 2026U.S. Food and Drug Administration Approves BioMarin's PALYNZIQ® (pegvaliase-pqpz) for Adolescents 12 Years of Age and Older with Phenylketonuria (PKU)
The FDA's expanded approval for BioMarin's PALYNZIQ for adolescents significantly grows the drug's addressable market. This should boost long-term ...
Feb 28, 2026